As ever, the past month has seen psychedelic research continue to accelerate across medicine, technology and commercial markets. Breakthroughs in molecular chemistry, clinical trials for neurodegenerative conditions, and shifting public perceptions of these substances are driving increasingly rapid expansion from non-hallucinogenic compounds and chronic pain management to new clinical applications and industry growth as a whole.
Regulatory Pathways
An FDA hearing carried out on 14th September 2026, entitled: “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing”, highlighted that there continues to be a marked lack of consensus as to how psychedelic medicine should be both regulated and administered. The hearing is one of the earliest implementations of Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness,” issued by the Trump administration on April 18, 2026. While enthusiasm remains high, clinical testimony has revealed deep divisions over safety, efficacy, and providers' credentials. Rajan Dunne, for example, a psychiatrist at Shepherd Pratt, argued that "good psychedelic care requires the full scope of psychiatric expertise." She also called for mandatory psychiatric oversight. On the other hand, nurse practitioners like Tina Braddock disagreed, stating that there is already an existing, licensed nursing workforce that is “already here, trained, deployable now.”
This debate at a federal level is occurring concurrently with rapid legislative movements in individual states. In Virginia, for example, lawmakers are in the process of preparing a framework for the approval of psilocybin, due to the anticipated shift in federal scheduling. Similarly, New Mexico has already opened the application process for permitting psychedelic mushroom producers under a new state program. This somewhat disjointed approach very much mirrors the early days of cannabis legislation. State-level initiatives outpaced federal guidance and created a fragmented regulatory environment across the country.
Fundamental questions definitely remain as to the exact role of these powerful substances in psychotherapy. Clinical psychologists presented existing controlled trial data suggesting that the therapeutic relationship is paramount. They also expressed concern that the commercialisation of future delivery models may well strip therapy from the process entirely, purely to reduce costs. A livestream of the hearing can be found on YouTube.
Anxiety Therapy
DT120, a synthetic formulation of lysergic acid diethylamide (LSD), developed by Definium Therapeutics, is rapidly advancing towards federal approval. A single 100-microgram dose of DT120 was said to reduce scores on an anxiety scale by 9.8 points after 12 weeks, compared with a 4.7-point decline for placebo. It is likely to be awarded federal approval, potentially as early as 2027.
Rob Barrow, chief executive Officer of Definium Therapeutics, said that the new data "confirmed the unprecedented advocacy of DT120 in GAD.” He reinforced the company's confidence in the drug's future potential as no severe drug-related adverse events or suicidality signals were observed throughout.
This particular clinical development is notable because it marks the first time a classic psychedelic derivative has completed two replicated phase 3 trials for GAD. Unlike currently approved treatments that require continuous daily administration, DT120 relies on a single-dose treatment model designed to promote sustained neuroplasticity. Following a federal review meeting, scheduled for late 2026, Definium plans to officially submit a new drug application in the first half of 2027. This could well fundamentally alter the current treatment options for individuals suffering from chronic anxiety conditions.
Non-Hallucinogenic Compounds
Researchers are in the process of deconstructing classic psychedelics to isolate their therapeutic properties from their hallucinatory effects. Chemists at UC Davis, California, have been able to successfully dismantle the complex four-ring structure of LSD and test these simplified variations of the molecule in animal models. The study, published in Proceedings of the National Academy of Sciences, discovered that a particular two-ring derivative proved to be the smallest molecule capable of triggering a hallucinogenic response, but another variant demonstrated the exact opposite effect. This particular analogue, known as UCD0076, in fact acted as a powerful antipsychotic in mice. It appeared to completely block the behavioural symptoms which are typically associated with psychosis and amphetamine exposure. This was achieved without impeding normal movement. By breaking the molecule down into its constituents and reconstructing it in novel ways, the researchers have engineered a compound that may be effective for tackling health conditions like schizophrenia, without inducing a potentially dangerous psychedelic trip.
Alongside this, the biotechnology sector is in the process of securing intellectual property for similar non-hallucinogenic compounds. Enveric Biosciences recently received a notice of allowance from the US Patent and Trademark Office for its EVM401 series. This portfolio of compounds consists of proprietary methylone-inspired mescaline derivatives, which are specifically designed to promote neuroplasticity without inducing hallucinatory effects.
These compounds have been structurally modified to eliminate any hallucinogenic effects while maintaining their therapeutic potential. The EVM401 series is designed as a potential treatment for issues such as post-traumatic stress disorder (PTSD) and a variety of other psychiatric conditions. The modifications also appear to improve the metabolic stability of the drug. This could potentially make it convenient for oral administration. Both of these advancements highlight a new and rapidly growing strategy in the pharmaceutical industry. The foundational architecture of psychedelic molecules is slowly being repurposed in an attempt to create accessible, non-hallucinogenic treatments for severe mental health disorders.
Neuropathy Prevention
In the field of oncology, researchers have uncovered a potential entirely new application for psychedelic compounds. A recent study, published in the journal Science, suggests that psilocybin could prevent chemotherapy-induced peripheral neuropathy (CIPN), which is a particularly debilitating and extremely painful form of nerve damage often caused by chemotherapy. The study showed that mice that received just two doses of psilocybin, shortly prior to being treated with cisplatin, a common chemotherapy drug, prevented the development of pain hypersensitivity. Crucially, the addition of the psychedelic treatment did not seem to interfere with the chemotherapy's ability to shrink tumours. The researchers discovered that psilocybin has the ability to protect nerve endings by maintaining the movement of mitochondria along the nerve fibres. This movement of mitochondria is a vital cellular process that is usually disrupted by currently available cancer treatments.
“This is the first time where psilocybin has been used as a neuroprotective agent,” said Patrick Dougherty, one of the authors of the paper, and a professor at the University of Texas MD Anderson Cancer Center.
As the clinical potential of psychedelics is better understood, oncology networks are rapidly mobilising to integrate these therapies safely. The Canadian Network for Psychedelic-Assisted Cancer Therapy ('CAN-PACT') is actively engaged in establishing national frameworks for clinician training, patient engagement and clinical research. This is to ensure that cancer patients can safely access psychedelic care.
Psychedelics and Anaesthetics: Mirror-Image Brain Effects
A recent study led by the University of Michigan Medical School has been able to map the underlying network organisation of the brain across different states of consciousness.
Using functional magnetic resonance imaging (fMRI), researchers were able to compare the brain activity of participants under the influence of psychedelics like psilocybin and LSD, and anaesthetics like nitrous oxide. Psychedelics and anaesthetics appear to create “mirror image” patterns of large-scale brain organisation.
While previous pharmacological research has analysed the neurological impact of particular drugs in isolation, this study deliberately compared the two distinct classes of compounds against baseline waking consciousness.
Rui Dai, PhD, one of the study authors, from the Department of Anesthesiology and Center for Consciousness Science at Michigan Medicine, states that the data showed that during psychedelic states, the brain becomes more globally connected, more efficient in communication and more dynamic, while anesthetic states are the opposite.”
Simply put, psychedelics and anaesthetics alter how easily information travels across the brain and the complexity of interaction between brain regions. This provides evidence that the neural mechanics of consciousness are very much tied to how the brain integrates and segregates information across its various networks.
Sacred Tourism
The commercialisation of psychedelics is rapidly expanding beyond clinical settings. This has given rise to an extremely lucrative wellness tourism industry. A new report published by Globetrender, in collaboration with Beckley Retreats, projected that the global psychedelic drugs market will reach $5.16 billion by 2034. Wealthy travellers who are often referred to as "intentional seekers" are often moving away from traditional luxury holidays and instead seeking out profound personal transformation. Modern retreats in places like the Netherlands and Jamaica combine high-end hospitality with legal psilocybin and truffles. The psychedelic experience is paired with rigorous therapeutic integration, breathwork and long-term aftercare, designed to ensure lasting change.
However, this is placing severe pressure on the traditional medicines and ecosystems that support them. Western psychedelic tourists are also flocking to places like South America to participate in ceremonies involving the San Pedro cactus. For more than three millennia, indigenous cultures across Peru, Ecuador, and Bolivia have used the cactus in a ritual context to promote emotional healing and unity with nature. The sudden influx of tourists seeking out this culturally significant substance raises complex ethical questions.
Psychedelic wellness is no longer a countercultural niche. It is a multibillion-dollar luxury sector. Those responsible for these new retreats will have to balance the scientific credibility of these substances alongside patient safety. However, this cannot be done without paying sufficient attention to the urgent need for environmental conservation alongside a deep respect for the indigenous traditions being co-opted.
Metabolic Health
New clinical and epidemiological data suggest that psychedelic compounds may influence human metabolic health and dietary behaviours. A phase 2 trial conducted in collaboration with Melbourne’s Swinburne University of Technology and Entropy Neurodynamics has evaluated TRP8803, which is an intravenously infused formulation of psilocin, in this context. The hope is that it will be a potential treatment for severe binge eating disorder.
The 12-week follow-up data from the study have shown an unprecedented durability of effect. Following the administration of just two infusions of TRP880, half of the participants achieved complete clinical remission. This is defined as zero binge eating episodes during the entire 84-day observation period. Across the entire study, weekly occurrences of binge eating remained 73% below the pre-treatment baseline. Jason Carroll, chief executive of Entropy, stated that results provide "increasing clinical validation of our precision controlled approach”. Crucially, this powerful therapeutic response does not require daily medication.
Further epidemiological research has indicated that classical psychedelics can shift overarching dietary patterns. A recent observational study published in the journal Scientific Reports analysed data from more than 21,800 adults. Researchers discovered that lifetime use of psilocybin and LSD was significantly associated with a higher likelihood of adopting a vegetarian diet as well as stronger pro-environmental attitudes. Specifically, recent psilocybin use appears to correlate with increased wholemeal bread consumption and reduced intake of red meat.
This shift towards vegetarianism appears to be very much mediated by the adoption of pro-environmental attitudes following exposure to psychedelics. While researchers have, of course, cautioned that the observational design cannot establish whether psychedelic use preceded or caused the dietary differences, this large-scale data is considered alongside the clinical data from the TRP8803 trial. It does appear to illustrate that psychedelic therapies have potential in this context.
Widespread Commercial and Grassroots Expansion
Industry expansion and the commercialisation of psychedelic medicine continue to experience rapid growth. This is driven by increasing scientific validation of their efficacy and escalating investment across the biotechnology sector. The global market for psychedelic mushrooms is projected to reach at least $3 billion by 2033. This is fuelled by advances in controlled cultivation, rigorous testing, and the integration of artificial intelligence systems to monitor the environment during production. Pharmaceutical companies and research organisations are all focused on improving dosage accuracy, metabolic stability, and regulatory compliance in the hopes of transitioning these compounds into mainstream medicine.
This macro-level expansion is mirrored by grassroots and regional commercialisation. In Michigan, for example, the annual “Entheofest” festival recently returned to the University of Michigan campus. This highlights the flourishing local industry with an expanding network of specialised shops and advocacy groups. This social normalisation provides further foundations for broader clinical acceptance.
However, Deputy Police Chief Melissa Overton said in a statement that: “We remind Entheofest attendees that the city of Ann Arbor’s resolution regarding entheogenic plants and fungi does not change state or federal law. Psilocybin and psilocin remain controlled substances under Michigan law,” which again illustrates the incongruity of the current legal situation in the US.
Final Thoughts
The marked increase in the pace of both psychedelic research and commercial applications is a pivotal moment in modern medicine and culture. The landscape is shifting at an unprecedented rate, and clinical trials continue to reveal potential new applications in spaces such as oncology, metabolic health and chronic anxiety. However, as commercial investment increases and public perception continues to soften, significant hurdles remain.
Establishing safe clinical protocols for vulnerable populations and balancing ecological sustainability against market demand will dictate the long-term viability of the sector as a whole. With worldwide regulatory change seemingly very near on the horizon, the integration of these compounds into mainstream healthcare will rely on rigorous scientific evidence as well as collaborative policymaking and a sustained commitment to safety.